抗体偶联药物治疗尿路上皮癌的研究进展

Advances in antibody-drug conjugate in the treatment of urothelial carcinoma

尿路上皮癌(urothelial carcinoma,UC)是泌尿系统常见的恶性肿瘤,在手术、化疗和免疫治疗等多种治疗措施下,仍有部分患者经历疾病复发、转移,预后不佳。抗体偶联药物(antibody-drug conjugate,ADC)兼有抗体药物的靶向性和化疗药物的细胞毒性,是近年来癌症个体化精准治疗的研究热点,成为这些患者新的选择。目前ADC治疗UC相关临床试验成果颇丰,靶向Nectin-4的Enfortomab Vedotin、靶向TROP-2的Sacituzumab Govitecan和靶向HER-2的Disitamab Vedotin已获批应用于临床,针对其他靶点的新型ADC也开始崭露头角。本文拟对最近的研究进展进行综述。

Urothelial carcinoma(UC)is a common malignancy of the urological system.Under a variety of treatment measures,such as surgery,chemotherapy and immunotherapy,some patients still suffer disease recurrence and metastasis,leading to poor prognosis.Antibody-drug conjugate(ADC)combining the targeting of antibody drugs and the cytotoxicity of chemotherapeutic drugs,has recently become a research hotspot for individualized precision treatment of cancer and a new choice for these patients.At present,the clinical trials related to ADC in the treatment of UC have achieved fruitful results.Enfortomab Vedotin targeting Nectin-4,Sacituzumab Govitecan targeting TROP-2,and Disitamab Vedotin targeting HER-2 have been approved to be applied in clinical practice,and new ADCs for other targets have also begun to emerge.This article intends to review the latest research in this field.